Cuprina Holdings (Cayman) Limited (CUPR)
NasdaqCM
Fundamentals
Valuation and ratings
Cuprina Holdings (Cayman) Limited trades at USD3.34. We do not hold enough of the inputs to run a discounted cash flow on this company, so we publish no fair value for it rather than a number we would not defend.
About Cuprina Holdings (Cayman) Limited
Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, focuses on the development and commercialization of products for the management of chronic wounds. The company manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products used as a biological debridement tool for chronic wounds under the MEDIFLY brand name. It is also developing collagen dressings, including sponges, particles, and hydrogels using bullfrog collagen derived from the valorization of abattoir waste streams; and products using medical leeches for wound treatment. The company was founded in 2019 and is based in Singapore. Cuprina Holdings (Cayman) Limited operates as a subsidiary of Cuprina Holding Pte. Ltd.
The full research page for CUPR, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.